Compare Novartis AG (NVS) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Williams Companies Inc — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Williams Companies Inc trades at $72.66 (market cap $87.88B). The key difference: Novartis AG is far larger — about 3.4× Williams Companies Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | WMB | |
|---|---|---|
Market Cap | $298.18B | $87.88B |
Sector | Health | Energy |
52-Week High | $168.62 | $79.40 |
52-Week Low | $119.31 | $56.51 |
Enterprise Value | $339.50B | $118.51B |
Dividend Yield | 3.02% | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
WMB trades at $70.4, down 1.9% on the day, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year EBITDA guidance to $8.4 billion. Strong profitability is evident with a 25.18% net income margin and 24.02% ROE, though valuation ratios like P/E of 28.05 appear elevated. The recent $5.5 billion acquisition of Momentum Midstream aims to bolster growth in the Haynesville region.
Outlook remains positive with analyst consensus strongly bullish (79% buy ratings) and a $87.14 price target, implying significant upside. Risks include execution of the Momentum integration, volatile energy prices, and high debt levels. Cash flow stability from fee-based contracts supports the dividend, but net cash flow turned negative in 2026 forecasts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
